LumaCyte, Inc.

CHARLOTTESVILLE, VA · Founded 2012 · Biotech · Private

Label-free single-cell analysis platform for real-time bioprocess monitoring and cell phenotyping

Claim this profile

Follows are private to you and power your alerts

Updated · lumacyte.com

Sector
Biotech
Headquarters
CHARLOTTESVILLE, VA
Founded
2012
Latest Form D
$10M, Sep 2023
Total capital
$21.1M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$21.1M
8 Form D · last Sep 2023
37 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
5
9 pending · first 2023
Rank in peer group#38 of 342

Capital timeline

20142016201820202022FEDERAL ↑EQUITY ↓Cumulative $21.1M2nd Form D$6.8M
20142016201820202022FEDERAL ↑EQUITY ↓Cumulative $21.1M2nd Form D$6.8M

Latest events

  • Private capital raisedForm D · SEC · 8th filing$10M
  • Private capital raisedForm D · SEC · 7th filing$550K
  • Private capital raisedForm D · SEC · 6th filing$750K
  • Private capital raisedForm D · SEC · 5th filing$525K
  • Private capital raisedForm D · SEC · 4th filing$1.3M
  • Private capital raisedForm D · SEC · 3rd filing$1.2M
  • Private capital raisedForm D · SEC · 2nd filing$6.8M
  • Private capital raisedForm D · SEC · 1st filing$30K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#38 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Sean Jeffrey HartResearcherExecutive OfficerLinked by 5 patents
  • Dennis WalczewskiDirectorNamed in SEC Form D filings
  • Paul MeisterDirectorNamed in SEC Form D filings
  • Pete BuzyDirectorNamed in SEC Form D filings
  • Renee HartExecutive Officer, DirectorNamed in SEC Form D filings
  • Robert HeiserDirectorNamed in SEC Form D filings

What it has protected

USPTO · 5 granted of 14
Show all 14 patent records
  • Culture Biosciences Inc.Similar federal contract value in Biotech · null in contracts
  • Pandion TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • BRITEBIO, INC.Similar federal contract value in Biotech · null in contracts
  • Surface Ophthalmics, Inc.Similar federal contract value in Biotech · null in contracts
  • MethylGene Inc.Similar federal contract value in Biotech · null in contracts
  • OtonomySimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .